Free Trial
→ Your Retirement Is Caught in the Crossfire (From Premier Gold Co) (Ad)

PainReform 8/15/2024 Earnings Report

PainReform logo
$1.75 -0.17 (-8.85%)
As of 04/8/2025 03:58 PM Eastern
Earnings HistoryForecast

PainReform EPS Results

Actual EPS
-$1.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PainReform Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PainReform Announcement Details

Quarter
Date
8/15/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Remove Ads

PainReform Earnings Headlines

PainReform Ltd: PainReform Provides Year-End Business Update
April 8 at 12:04 PM | finanznachrichten.de
PainReform says shareholder equity now exceeds required threshold
April 8 at 12:04 PM | markets.businessinsider.com
Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
April 9, 2025 | Premier Gold Co (Ad)
PainReform Expands into Clean Energy with DeepSolar Acquisition
April 7 at 5:56 PM | tipranks.com
PainReform Provides Year-End Business Update
April 7 at 5:00 PM | globenewswire.com
PainReform’s Shareholder Meeting Adjourned Due to Lack of Quorum
April 3, 2025 | tipranks.com
See More PainReform Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PainReform? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PainReform and other key companies, straight to your email.

About PainReform

PainReform (NASDAQ:PRFX), a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

View PainReform Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles